Dhawan Ravinder

Use of Patient-Reported Outcomes (PROs) to Assess Prognosis, Toxicity, and Response: The Bortezomib Experience in Relapsed and Refractory Multiple Myeloma (MM).

D. Esseltine, D. Dubois, C. Loge, 2004 .